Blueheel is spot on. He most likely had access to

Blueheel is spot on. He most likely had access to the most recent private presentation from the past Paulson raise.

There are a few things that will happen in 2023:

1. The hold will be lifted likely in the next one to two weeks. All of the data was submitted to the FDA more than three weeks ago and they have 30 days to respond. From what I know about Cyrus, it was done thoroughly and completely.

2. Once the hold is lifted, we will attract a partner to fund our trials in oncology.

3. The company will re-brand with a new name which makes perfect sense. The old leadership that nearly ran this company into the ground is completely gone and this is a totally new team, focused on different indications, etc. – – effectively a new company with the same extremely promising drug.

4. We will, indeed receive a significant amount of money from Amarex this year – – the case against them is very clear cut.

5. A large NASH trial will be initiated and we will make progress toward enrollment. We will be one of several companies that make a ton of money in this massive market.

I have been invested for seven years and became extremely negative and disillusioned during the last year of Nader’s leadership. I voiced those concerns publicly, but finally decided to simply keep my mouth shut, as I am generally a positive person.

But we are in a completely different ballgame now. Cyrus is all business / no BS - the real deal. I know this from direct experience.

No, I won’t respond to any of the troll comments that I’m sure I will get from this post – – because I know a lot more about what is going on behind the scenes than any of them do, and they are likely employed by short-sellers anyway. but to be very clear, we are close to a value inflection point here as we finally have world class leadership paired with a world class drug.

Good luck longs. 2023 is (finally) our year.